Research Topics
| A A MillerSummaryAffiliation: Wake Forest University School of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602)Antonius A Miller
Comprehensive Cancer Center of Wake Forest University, Medical Center Blvd, WinstonSalem, NC 27157, USA
J Thorac Oncol 5:380-4. 2010..The primary objective of this study was to determine the efficacy of second-line dasatinib in patients with chemosensitive (relapse or progression > or =90 days after completing first-line therapy) small cell lung cancer...- Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301Antonius A Miller
Comprehensive Cancer Center of Wake Forest University, Wake Forest University School of Medicine, Winston Salem, NC, USA
J Clin Oncol 27:1800-5. 2009..We sought to characterize the pharmacokinetics (PK) and determine a tolerable dose of oral sorafenib in patients with hepatic or renal dysfunction... 
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303)Antonius A Miller
Wake Forest University, Winston Salem, North Carolina, USA
J Thorac Oncol 3:1159-65. 2008..We investigated dose-dense docetaxel and cisplatin in patients with measurable non-small cell lung cancer in a randomized phase II study without [A] or with [B] a putative chemoprotective agent, BNP7787...
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101Antonius A Miller
Wake Forest University School of Medicine, Winston Salem, NC 27157 1082, USA
J Clin Oncol 25:3055-60. 2007..We investigated dose and pharmacokinetics of erlotinib in patients with hepatic dysfunction or renal dysfunction...- Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002Antonius A Miller
Comprehensive Cancer Center, Wake Forest University, Winston Salem, North Carolina, USA
J Thorac Oncol 2:645-51. 2007.... - Phase I study of lenalidomide in solid tumorsAntonius A Miller
Wake Forest University, Comprehensive Cancer Center, Winston Salem, NC 27157, USA
J Thorac Oncol 2:445-9. 2007..The secondary objective was to document any antitumor activity... - Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancerAntonius A Miller
Comprehensive Cancer Center, Wake Forest University, Winston Salem, North Carolina, USA
J Thorac Oncol 1:832-6. 2006..We hypothesized that thalidomide would improve the response and toxicity profile of chemotherapy with carboplatin and irinotecan... - Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancerAntonius A Miller
Comprehensive Cancer Center of Wake Forest University, Section on Hematology and Oncology, Medical Center Boulevard, Winston Salem, NC 27157, United States
Lung Cancer 54:379-85. 2006..In conclusion, neutropenia and thrombocytopenia were dose-limiting. The maximum tolerated dose (MTD) is topotecan 3mg/day p.o. days 1-5, carboplatin AUC 5i.v. day 6, and etoposide 150 mg/day p.o. days 6-10 with filgrastim... - Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004)Antonius A Miller
Comprehensive Cancer Center of Wake Forest University, Medical Center Blvd, Winston Salem, NC 27157, USA
Lung Cancer 48:399-407. 2005..This Phase II trial was designed to determine the response rate, survival, failure-free survival, and toxicity of second-line therapy with karenitecin in patients with relapsed or refractory non-small cell lung cancer (NSCLC)... - Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763Antonius A Miller
Wake Forest University, Winston Salem, North Carolina 27157, USA
Clin Cancer Res 10:8325-31. 2004..v. over 3 hours to female patients, and to evaluate prospectively the relationships between the following: body surface area and toxicity; body surface area and pharmacokinetics; and pharmacokinetics and toxicity... - Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposideA A Miller
Veterans Affairs Medical Center Memphis, 1030 Jefferson Avenue, Memphis, TN 38104, USA
Lung Cancer 33:241-8. 2001..73 to 1.69 ng/ml, and mean etoposide concentrations ranged from 60 to 230 ng/ml. This sequence of topotecan, carboplatin, and etoposide appeared tolerable and active. Neutropenia was the dose-limiting toxicity... - Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062)A A Miller
University of Tennessee, Memphis, Tennessee 38163, USA
Clin Cancer Res 3:719-25. 1997..001). Neither EC nor Efree showed a significant correlation with tumor response. A pharmacokinetic relationship between EC or Efree and age was found. A pharmacodynamic model could be developed for toxicity but not for tumor response... - A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancerBrian Center
Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27516, USA
J Thorac Oncol 5:69-74. 2010..This study sought to define the maximum tolerated dose of weekly docetaxel that could be given with daily gefitinib and concurrent thoracic radiation therapy... - Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732Harvey B Niell
University of Tennessee, Memphis, TN 31187, USA
J Clin Oncol 23:3752-9. 2005.... - Small cell lung cancer: have we made any progress over the last 25 years?Brian E Lally
Department of Radiation Oncology, Wake Forest University Health Sciences, Winston Salem, North Carolina, USA
Oncologist 12:1096-104. 2007..It is imperative that, whenever possible, patients be given the opportunity to participate in future clinical trials so that the survival for these patients can continue to improve... - A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancerW Jeffrey Petty
Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Winston Salem, North Carolina 27157, USA
J Thorac Oncol 2:197-202. 2007..This phase II clinical trial was performed using a non-platinum-based chemotherapy doublet. The impact of previously identified polymorphisms on clinical outcomes was assessed... - Using erlotinib to treat patients with non-small cell lung cancer who continue to smokeLynsay L Waller
Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Winston Salem, NC, USA
Lung Cancer 67:12-6. 2010..Individually, the selection and dosing of erlotinib for the treatment of lung cancer patients who continue to smoke is a clinical challenge... - The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033M J Naughton
Wake Forest University School of Medicine, Winston Salem, NC 27157 1063, USA
Qual Life Res 11:235-48. 2002..Brain involvement, being male, and higher depressive symptoms were also found to be borderline significant in predicting decreased survival in this patient population... - Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormoneW Jeffrey Petty
Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Winston Salem, North Carolina 27157, USA
Clin Cancer Res 15:7398-404. 2009..Secondary objectives were to assess toxicities, pharmacokinetics, clinical activity, and plasma biomarkers... - Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trialA William Blackstock
Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
Clin Lung Cancer 6:287-92. 2005..Interdigitating split-course thoracic RT delivered in 2.5-Gy fractions was tolerable in patients with limited-stage SCLC but did not provide a survival advantage... - Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary studyRobert Chin
Department of Medicine, Section of Pulmonary and Critical Care, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 1054, USA
Lung Cancer 37:1-6. 2002..Whether FDG-PET will replace other more established staging modalities remains to be determined by larger prospective randomized controlled studies... - Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancerA William Blackstock
Department of Radiation Oncology, Wake Forest University Comprehensive Cancer Center, Winston Salem, North Carolina 27516, USA
J Thorac Oncol 1:434-40. 2006..The safety of dose-escalated thoracic radiation concurrent with gemcitabine in patients with inoperable stage III non-small cell lung cancer has not been studied... - Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapyPeter E Clark
Department of Urology and Comprehensive Cancer Center, Wake Forest University Health Sciences, Winston Salem, North Carolina 27157, USA
Urology 67:1257-61. 2006..To report a prospective trial of lycopene supplementation in biochemically relapsed prostate cancer... - Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group BA William Blackstock
Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
J Clin Oncol 24:407-12. 2006..We investigated whether the disparity in survival would persist when patients were treated with similar therapies (ie, phase II/III Cancer and Leukemia Group B [CALGB] trials)... - The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results databaseBrian E Lally
Department of Radiation Oncology, Wake Forest University Health Sciences, Winston Salem, NC 27157 1030, USA
Cancer 110:911-7. 2007..This study was designed to investigate whether the mortality from heart disease, a manifestation of intercurrent disease after postoperative radiotherapy (PORT), has decreased over time for patients with nonsmall cell lung cancer (NSCLC)... - Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results databaseBrian E Lally
Wake Forest University Health Sciences, Department of Radiation Oncology, Medical Center Boulevard, Winston Salem, NC 27157, United States
Lung Cancer 64:226-31. 2009..In order to continue to improve clinical outcomes, clinical trials investigating new treatment paradigms are needed... - Body surface area in dosing anticancer agents: scratch the surface!Antonius A Miller
J Natl Cancer Inst 94:1822-3. 2002 - Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730)Rogerio C Lilenbaum
The Mount Sinai Comprehensive Cancer Center, 4306 Alton Rd, Miami Beach, FL, USA
J Clin Oncol 23:190-6. 2005..We compared the efficacy of combination chemotherapy versus single-agent therapy in patients with advanced non-small-cell lung cancer... - Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B studyCheri E Klein
Department of Biopharmaceutical Sciences, The University of Illinois at Chicago, 833 South Wood Street (MC 865, Chicago, IL 60612, USA
Cancer Chemother Pharmacol 57:199-206. 2006..The optimal schedule cannot be determined from this study, as there was no evident relationship between any pharmacokinetic parameter and clinical response... - Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762)Stuart M Lichtman
University of Chicago, Chicago, USA
J Clin Oncol 24:1846-51. 2006..45). CONCLUSION: Although paclitaxel CL(tb) decreases with increasing patient age, there is great interpatient variability. Cooperative group studies to evaluate the effect of aging on pharmacokinetics are feasible... - A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871Lionel D Lewis
Sections of Clinical Pharmacology and Hematology Oncology, Department of Medicine, Dartmouth Medical School, The Norris Cotton Cancer Center, Lebanon, New Hampshire 03756, USA
Clin Cancer Res 13:3302-11. 2007..We hypothesized that the pharmacokinetics and pharmacodynamics of docetaxel, an i.v. administered cytotoxic and substrate for CYP3A4, CYP3A5, and ABCB1, would differ between African-American and Caucasian patients... - Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105Mark A Socinski
Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, NC 27599, USA
J Clin Oncol 26:2457-63. 2008..To evaluate 74 Gy thoracic radiation therapy (TRT) with induction and concurrent chemotherapy in stage IIIA/B non-small-cell lung cancer (NSCLC)... - Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431Everett E Vokes
University of Chicago Medical Center and Cancer and Leukemia Group B, Chicago, IL, USA
J Clin Oncol 20:4191-8. 2002.... - 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808Jeffrey A Bogart
Department of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY 13210, USA
Int J Radiat Oncol Biol Phys 59:460-8. 2004..To prospectively evaluate the feasibility of delivering 70 Gy once-daily thoracic radiotherapy (TRT), concurrent with chemotherapy, in the treatment of limited-stage small-cell lung cancer (L-SCLC)... - The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspectiveMark J Ratain
University of Chicago, Chicago, Illinois, USA
Clin Cancer Res 12:3612s-6s. 2006..It is anticipated that the results of the current studies will contribute significantly to the goal of individualizing cancer treatment...